|
Are National Comprehensive Cancer Network (NCCN) Evidence Blocks (EB) Affordability Ratings (AR) representative of real-world costs? An evaluation of advanced non small cell lung cancer (aNSCLC). |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech; Kite, a Gilead company; Seagen |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Bayer Schering Pharma; Bristol-Myers Squibb; Flatiron Health |
|
|
Consulting or Advisory Role - Avanir; Otsuka |
Research Funding - Amgen; Biogen; Genentech; Otsuka; Purdue Pharma; Sanofi; Shire |
|
|
|
Stock and Other Ownership Interests - Genentech |
Travel, Accommodations, Expenses - Genentech |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Allergan; Roche |
Research Funding - Genentech/Roche |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Genentech |
Travel, Accommodations, Expenses - Genentech |
|
|
Consulting or Advisory Role - Axovant Sciences; Johnson & Johnson; Lundbeck; Novartis; Partnership for Health Analytic Research; Precision Health Economics; Takeda; Veritech Corporation |
Research Funding - Biogen; GE Healthcare; Genentech; Gilead Sciences; Merck; National Pharmaceutical Council; Novartis; Otsuka; Pfizer; PhRMA Foundation; Purdue Pharma; Sanofi; Vertex |